lenalidomide,temsirolimus
not tagged
['dlbcl', 'lymsm', 'cml']
so surreal to see our tem/len study cited in dr. advani's #17icml talk on agents in relapsed/refractory lbcl. not great activity in dlbcl, but orr 80% in chl! potentially useful for bridging to allo. cc #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈